AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q1 FY23 results · Apr–Jun 2022
AstraZeneca Pharma India reported revenue from operations of ₹232.33 crore (up 32.5% from Q1 FY22) and net profit of ₹20.15 crore (up 96.7% from Q1 FY22) for Q1 FY23 (Apr–Jun 2022), on a standalone basis.
| Item | Q1 FY23 | Q1 FY22 | YoY | Q4 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 232.33 | 175.40 | +32.5% | 231.96 | +0.2% |
| Other income | 4.11 | 2.90 | +41.9% | 3.68 | +11.7% |
| Total income | 236.45 | 178.30 | +32.6% | 235.65 | +0.3% |
| Profit before tax | 27.30 | 13.50 | +102.2% | 37.03 | −26.3% |
| Net profit for the period | 20.15 | 10.24 | +96.7% | 27.98 | −28.0% |
| EPS, basic (₹) | 8.06 | 4.10 | +96.8% | 11.19 | −28.0% |
| Net margin (%) | 8.7 | 5.8 | 12.1 |
Standalone
- Filed with BSE
- 09 Aug 2022, 17:55 IST
- Board meeting
- 08 Aug 2022
- Period
- 01 Apr 2022 to 30 Jun 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE